Relmada Therapeutics Résultats passés
Passé contrôle des critères 0/6
Relmada Therapeutics a connu une croissance annuelle moyenne de ses bénéfices de 13.3%, tandis que le secteur Pharmaceuticals a vu ses bénéfices croître de en hausse à 9.7% par an.
Informations clés
13.34%
Taux de croissance des bénéfices
27.15%
Taux de croissance du BPA
| Pharmaceuticals Croissance de l'industrie | 5.95% |
| Taux de croissance des recettes | n/a |
| Rendement des fonds propres | -26.92% |
| Marge nette | n/a |
| Dernière mise à jour des bénéfices | 31 Mar 2026 |
Mises à jour récentes des performances passées
Recent updates
Nouveau récit • May 16
Bladder Cancer Catalyst Faces Clinical And Patent Hurdles Yet Future Potential Remains
Catalysts About Relmada Therapeutics Relmada Therapeutics is a clinical stage biopharmaceutical company focused on developing therapies for non muscle invasive bladder cancer and compulsivity related neuropsychiatric disorders. What are the underlying business or industry changes driving this perspective?
Nouveau récit • Mar 20
Phase III Bladder Cancer Catalyst Will Drive Long Term Value For This Biotech
Catalysts About Relmada Therapeutics Relmada Therapeutics is a clinical stage biopharmaceutical company focused on developing NDV-01 for non muscle invasive bladder cancer and sepranolone for compulsivity related neurological disorders. What are the underlying business or industry changes driving this perspective?
Nouveau récit • Mar 05
Bladder Cancer And Compulsive Disorder Therapies Will Support A Stronger Long Term Outlook
Catalysts About Relmada Therapeutics Relmada Therapeutics is a clinical stage biopharmaceutical company developing NDV-01 for non muscle invasive bladder cancer and sepranolone for compulsive behavior disorders such as Prader Willi syndrome. What are the underlying business or industry changes driving this perspective?Seeking Alpha • Mar 21
Relmada Therapeutics: Run Up Into Results May Resume Following This Drop
Summary RLMD plans to report results from the phase 3 Reliance II study of REL-1017, as an adjunctive treatment for major depressive disorder, in H2 2024. The current timeline for completion of enrolment in Reliance II may suggest a slight slippage, but my position on the potential for a run up is unchanged. RLMD notes it has cash to complete its current studies Reliance II and Relight, as well as a phase 1 study of modified release psilocybin. Read the full article on Seeking AlphaArticle d’analyse • Mar 13
Here's Why We're Watching Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Seeking Alpha • Jan 14
Relmada: Phase 3 Data Did Not Live Up To Phase 2 Benchmark
Summary Relmada Therapeutics is developing REL-1017, a therapy for CNS diseases that targets hyperactive GluN2D channels in NMDA receptors. Phase 2 trial showed a rapid and sustained antidepressant effect in patients who did not respond to standard antidepressants. Phase 3 trial missed its primary endpoint, but post-hoc analysis showed a robust difference between REL-1017 and placebo when excluding certain clinical sites. Read the full article on Seeking AlphaArticle d’analyse • Dec 04
Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Deliver On Growth Plans?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Article d’analyse • Aug 29
Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Invest In Growth?
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...Article d’analyse • May 07
We're Keeping An Eye On Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Article d’analyse • Dec 15
We're Keeping An Eye On Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Seeking Alpha • Oct 14
Relmada Downgraded at Truist, Guggenheim in wake of depression candidate failure
Truist and Guggenheim have downgraded Relmada Therapeutics (NASDAQ:RLMD) to hold and neutral, respecitvely, following the failure of phase 3 depression REL-1017. Truist lowered its price target to $10 from $90 (~54% upside based on Thursday's close) while Guggenheim doesn't have a target. Truist analyst Joon Lee wrote that based on conversations with key opinion leaders, REL-1017 would have faced headwinds on approval due to a REMS requirement and DEA scheduling. Guggenheim is removing its sales estimated for REL-1017. Analyst Yatin Suneja wrote that Relmada could still salvage the candidate by either adding substantially more participants to the RELIANCE 1 trial or persuade regulators to exclude patients from the handful of sites where a high placebo effect was observed. However, Suneja conceded the second option is less likely. Seeking Alpha's Quant Rating views Relmada (RLMD) as a hold with high marks for momentum and growth.Seeking Alpha • Sep 14
Relmada Therapeutics: Initiating With A Strong BUY; Key Phase 3 Short-Term Catalysts Lined Up
Summary We initiate Relmada Therapeutics with a Strong BUY rating due to our high degree of conviction on REL-1017's clinical success during the phase 3 trial. The phase 2 data showed that REL-1017 is rapid, effective, safe, and durable. Looking at the robust mechanism of action and phase 2 clinical data, we believe the clinical data to hold in phase 3. The key catalyst is REL-1017's phase 3 data that is expected in Q4 22 which we believe will move the stock price substantially and we are planning to start establishing a small option-sized position of the ticker. Background Relmada Therapeutics (NASDAQ:RLMD) is a US-based, pre-commercial stage biotech developing therapies for depressive disorders. The company is trading at a 700M enterprise value and holds 200M cash, which is a highly robust cash runway for a clinical-stage company. Accordingly, we initiate RLMD with a strong BUY rating. RLMD IR deck (RLMD IR deck) The unique mechanism of action of REL-1017 is key for best-in-class efficacy and safety REL-1017 is a novel first-in-class compound formulation of oral dextromethadone currently being studied to target depressive disease. We highlight that REL-1017 is the only compound that uniquely targets NMDA receptors to treat depression. The drug's key compositions are dextromethadone, the purified "d" enantiomer of methadone. We note that this is important for the drug's exceptional safety, a racemic mixture of "d" and "l" methadone is currently used to treat patients with opioid addiction problems; however, the "d" form lacks substantial opioid receptor activity and instead works as an NMDA receptor antagonist and channel blocker, similar to ketamine. Phase 2 efficacy and safety data points were effective and clean, we are optimistic about the success of the drug in phase 3 We highlight the key takeaways from phase 2 trials i) effective and durable anti-depressant effects on all tested scales, ii) rapid onset of action, with detected efficacy by day 4, iii) robust safety without opioid-related adverse events, psychotomimetic adverse events, and metabolic side-effects were shown, and iv) convenience - the drug is orally administered with a QD tablet formulation. RLMD IR deck (RLMD IR deck) Key findings are: Subjects in both the REL-1017 25 mg and 50 mg treatment groups experienced statistically significant improvement of their depression compared to subjects in the placebo group on all efficacy measures, including: the MADRS; the Clinical Global Impression – Severity (CGI-S) scale; the Clinical Global Impression – Improvement (CGI-I) scale; and the Symptoms of Depression Questionnaire (SDQ). The improvement on the MADRS appeared on Day 4 in both REL-1017 dose groups and continued through Day 7 and Day 14, seven days after treatment discontinuation, with p-values <0.03 and large effect sizes (a measure of quantifying the difference between two groups), ranging from 0.7 to 1.0. Similar findings emerged from the CGI-S and CGI-I scales. Source: company IR deck We believe REL-1017's remarkable potency combined with the drug's rapid and sustained effects make it the best-in-class agent currently being developed. We highlight that REL-1017 demonstrated impressive separation from placebo on the MADRS endpoint on Day 14. In comparison to SOCs, the ~9.4–10.4 reduction compared to placebo is more than double the reduction seen with approved anti-depressants. This level of efficacy was achieved in a more challenging, treatment-refractory patient population, which is highly promising moving forward in terms of commercial potential. Keeping the difference in study design in mind, if we compare REL-1017 to fellow NMDA receptor antagonists, Spravato, Spravato only demonstrated a 4.0 reduction in MADRS score over placebo at day 28 in its pivotal TRANSFORM-2 trial. RLMD IR deck (RLMD IR deck) RLMD IR deck (RLMD IR deck) as shown above (REL-1017 phase 2 study safety data (Company IR) No serious treatment-emergent adverse events were shown. In terms of safety, the global safety profile seems superior to Spravato as there were no reported dissociative/psychomimetic effects. Furthermore, there were no signs of opioid withdrawal upon treatment discontinuation. The most common adverse events included mild to moderate headache, nausea, and sedation, which were evenly distributed across the treatment arms, which does not concern us, and we believe the drug has a robust profile with a favorable risk/benefit as an MDD therapeutic candidate. Furthermore, we believe REL-1017's oral formulation to be more convenient for patients than Spravato's intranasal administration as it is less discrete. We believe the phase 3 trial design is robust and the endpoints are achievable for the drug based on their robust phase 2 performanceSeeking Alpha • Aug 09
Relmada Therapeutics receives FDA fast track tag for REL-1017 to treat depression
Relmada Therapeutics (NASDAQ:RLMD) said on Tuesday the U.S. Food and Drug Administration had granted Fast Track designation to its drug, REL-1017, as a monotherapy to treat major depressive disorder. (RLMD) rose 3.3% premarket. For a fast track drug, the company must show some advantage over current therapy, such as superior effectiveness, effect on serious outcomes or improved effect on serious outcomes, and avoiding serious side effects of an available therapy. A drug that receives Fast Track designation is eligible for Accelerated Approval and Priority Review.Article d’analyse • Jul 14
We're Hopeful That Relmada Therapeutics (NASDAQ:RLMD) Will Use Its Cash Wisely
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Article d’analyse • Feb 26
Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Deliver On Growth Plans?
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Seeking Alpha • Jan 28
4 Clinical Catalysts On Tap For Relmada In 2022
RLMD is set to produce results in 2022 from four clinical trials of REL-1017, its novel antidepressant. Late-stage failures of antidepressants are not unheard of, so I provide a cautionary tale to RLMD longs. The timing of readouts allows for an interesting potential trade, avoiding exposure to an earlier study which I feel has more downside than upside potential.Article d’analyse • Nov 04
Is Relmada Therapeutics (NASDAQ:RLMD) In A Good Position To Invest In Growth?
We can readily understand why investors are attracted to unprofitable companies. For example, although...Seeking Alpha • Jun 28
Our First Look At Relmada Therapeutics
Relmada Therapeutics, Inc.’s (RLMD) sole clinical asset, oral antidepressant therapy esmethadone, is undergoing two pivotal trials for the treatment of MDD. Phase 2 study data demonstrate a rapid onset of action that no other currently approved oral therapy can boast. Despite esmethadone’s promise, Axsome Therapeutics (AXSM) has a similar oral candidate (AXS-05) with a novel MOA and August 22nd, 2021 PDUFA date, suggesting an ~18-month head start. A full investment analysis is presented in the paragraphs below.Article d’analyse • Jun 28
We're Not Very Worried About Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Article d’analyse • Mar 09
Here's Why We're Not Too Worried About Relmada Therapeutics' (NASDAQ:RLMD) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Article d’analyse • Jan 15
What Percentage Of Relmada Therapeutics, Inc. (NASDAQ:RLMD) Shares Do Insiders Own?
If you want to know who really controls Relmada Therapeutics, Inc. ( NASDAQ:RLMD ), then you'll have to look at the...Ventilation des recettes et des dépenses
Ventilation des recettes et des dépenses
Comment Relmada Therapeutics gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 31 Mar 26 | 0 | -59 | 37 | 20 |
| 31 Dec 25 | 0 | -57 | 32 | 24 |
| 30 Sep 25 | 0 | -56 | 28 | 30 |
| 30 Jun 25 | 0 | -68 | 34 | 37 |
| 31 Mar 25 | 0 | -76 | 34 | 45 |
| 31 Dec 24 | 0 | -80 | 38 | 46 |
| 30 Sep 24 | 0 | -86 | 42 | 50 |
| 30 Jun 24 | 0 | -87 | 42 | 49 |
| 31 Mar 24 | 0 | -94 | 46 | 52 |
| 31 Dec 23 | 0 | -99 | 49 | 55 |
| 30 Sep 23 | 0 | -112 | 49 | 67 |
| 30 Jun 23 | 0 | -129 | 45 | 87 |
| 31 Mar 23 | 0 | -144 | 47 | 104 |
| 31 Dec 22 | 0 | -157 | 48 | 113 |
| 30 Sep 22 | 0 | -153 | 45 | 112 |
| 30 Jun 22 | 0 | -157 | 45 | 115 |
| 31 Mar 22 | 0 | -143 | 40 | 102 |
| 31 Dec 21 | 0 | -126 | 35 | 91 |
| 30 Sep 21 | 0 | -112 | 32 | 79 |
| 30 Jun 21 | 0 | -86 | 29 | 57 |
| 31 Mar 21 | 0 | -71 | 28 | 44 |
| 31 Dec 20 | 0 | -59 | 25 | 34 |
| 30 Sep 20 | 0 | -43 | 22 | 23 |
| 30 Jun 20 | 0 | -30 | 18 | 12 |
| 31 Mar 20 | 0 | -23 | 11 | 11 |
| 31 Dec 19 | 0 | -15 | 7 | 8 |
| 30 Sep 19 | 0 | -18 | 5 | 7 |
| 30 Jun 19 | 0 | -17 | 5 | 7 |
| 31 Mar 19 | 0 | -17 | 6 | 5 |
| 31 Dec 18 | 0 | -17 | 5 | 5 |
| 30 Sep 18 | 0 | -11 | 4 | 4 |
| 30 Jun 18 | 0 | -9 | 4 | 3 |
| 31 Mar 18 | 0 | -7 | 4 | 2 |
| 31 Dec 17 | 0 | -6 | 5 | 1 |
| 30 Sep 17 | 0 | -6 | 5 | 1 |
| 30 Jun 17 | 0 | -6 | 6 | 1 |
| 31 Mar 17 | 0 | -8 | 7 | 2 |
| 31 Dec 16 | 0 | -8 | 7 | 2 |
| 30 Sep 16 | 0 | -9 | 9 | 4 |
| 30 Jun 16 | 0 | -3 | 10 | 6 |
| 31 Mar 16 | 0 | 6 | 9 | 8 |
| 31 Dec 15 | 0 | 6 | 9 | 10 |
| 30 Sep 15 | 0 | 14 | 8 | 10 |
Des revenus de qualité: RLMD n'est actuellement pas rentable.
Augmentation de la marge bénéficiaire: RLMD n'est actuellement pas rentable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: RLMD n'est pas rentable, mais a réduit ses pertes au cours des 5 dernières années à un taux de 13.3% par an.
Accélération de la croissance: Impossible de comparer la croissance des bénéfices de RLMD au cours de l'année écoulée à sa moyenne sur 5 ans car elle n'est actuellement pas rentable
Bénéfices par rapport au secteur d'activité: RLMD n'est pas rentable, ce qui rend difficile la comparaison de sa croissance des bénéfices de l'année écoulée avec celle du secteur Pharmaceuticals ( -5% ).
Rendement des fonds propres
ROE élevé: RLMD a un retour sur capitaux propres négatif ( -26.92% ), car il n'est actuellement pas rentable.
Rendement des actifs
Rendement des capitaux employés
Découvrir des entreprises performantes dans le passé
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/20 18:26 |
| Cours de l'action en fin de journée | 2026/05/20 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Relmada Therapeutics, Inc. est couverte par 10 analystes. 5 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Maxim Jacobs | Edison Investment Research |
| Farzin Haque | Jefferies LLC |
| Andrew Berens | Leerink Partners LLC |